Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
Teveten Plus | Eprosartan mesylate/ hydrochlorothiazide | Hypertension, Essential | List in a similar manner to other drugs in class | Complete | ||
Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete |